Enliven Therapeutics Inc. (NASDAQ: ELVN) reported updated results from its Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE